Jul. 15 at 2:10 PM
🧬
$INBS : Could FDA Approval Unlock the Next Leg Higher?
Intelligent Bio Solutions is developing a fingerprint based drug screening system that delivers fast, non invasive testing
On June 16, the company kicked off another FDA clinical study, marking another step toward its planned 510(k) submission and potential entry into the U.S. drug testing market
Recent Highlights:
🔹 FDA clinical program remains on track
🔹 135-patient U.S. multi site study underway
🔹 Operating in 35+ countries with 480+ active customer accounts
🔹 Q3 revenue increased 46% YoY to
$1.06M
🔹 Nine-month revenue reached
$3.07M, up 39% YoY
🔹 Gross margin climbed above 50%
🔹 Cash position increased to
$6.86M
🔹 Secured its 8th European patent while expanding manufacturing capacity
With several FDA milestones ahead, growing commercial traction, and improving financials, INBS looks like one to keep on the watchlist
Communicated Disclaimer: https://stockresearchtoday.com/inbs/
Sector Peers :
$OSUR $QDEL $DGX $LH